Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk
Low bone mineral density (BMD) is correlated with increased fracture risk. Whether greater BMD increases induced by osteoporosis drugs are related to greater decreases in fracture risk is controversial. We analyzed the relationship between BMD change and fracture risk in postmenopausal osteoporotic women receiving antiresorptive treatment. The analysis combined data from three pivotal risedronate fracture end-point trials. Women received risedronate (n = 2047) or placebo (n = 1177) daily for up to 3 yr. The BMD and vertebral radiographs were assessed periodically during 3 yr. The estimated risk of new vertebral fracture was compared between patients whose BMD increased and those whose BMD decreased. Risedronate-treated patients whose BMD decreased were at a significantly greater risk (p = 0.003) of sustaining a vertebral fracture than patients whose BMD increased. The fracture risk was similar (about 10%) in risedronate-treated patients whose increases in BMD were < 5% (the median change from baseline) and in those whose increases were ? 5% (p = 0.453). The changes in lumbar spine BMD explained only 18% (95% confidence interval [CI], 10%, 26%; p < 0.001) of risedronate's vertebral fracture efficacy. Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk.
bone mineral density, vertebral fractures, risedronate, surrogate measure, osteoporosis, antiresorptive therapy
255-261
Watts, Nelson B.
5c0d14e9-020d-4e1f-802a-163636c5f0ea
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Lindsay, Robert
9508787f-a0b6-4155-95f7-33c57e4f56a0
Eastell, Richard
b19615e4-bc97-4ddf-b8d7-7f48b7220228
Manhart, Michael D.
790677b6-b0b1-4d29-8458-5e795a3e4db0
Barton, Ian P.
5e0ccee1-81ef-49d3-bd45-ec29e95f26f7
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Adachi, Jonathan D.
b332030f-9df9-4fb8-8547-7192a37b2522
2004
Watts, Nelson B.
5c0d14e9-020d-4e1f-802a-163636c5f0ea
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Lindsay, Robert
9508787f-a0b6-4155-95f7-33c57e4f56a0
Eastell, Richard
b19615e4-bc97-4ddf-b8d7-7f48b7220228
Manhart, Michael D.
790677b6-b0b1-4d29-8458-5e795a3e4db0
Barton, Ian P.
5e0ccee1-81ef-49d3-bd45-ec29e95f26f7
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Adachi, Jonathan D.
b332030f-9df9-4fb8-8547-7192a37b2522
Watts, Nelson B., Cooper, Cyrus, Lindsay, Robert, Eastell, Richard, Manhart, Michael D., Barton, Ian P., van Staa, Tjeerd-Pieter and Adachi, Jonathan D.
(2004)
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Journal of Clinical Densitometry, 7 (3), .
Abstract
Low bone mineral density (BMD) is correlated with increased fracture risk. Whether greater BMD increases induced by osteoporosis drugs are related to greater decreases in fracture risk is controversial. We analyzed the relationship between BMD change and fracture risk in postmenopausal osteoporotic women receiving antiresorptive treatment. The analysis combined data from three pivotal risedronate fracture end-point trials. Women received risedronate (n = 2047) or placebo (n = 1177) daily for up to 3 yr. The BMD and vertebral radiographs were assessed periodically during 3 yr. The estimated risk of new vertebral fracture was compared between patients whose BMD increased and those whose BMD decreased. Risedronate-treated patients whose BMD decreased were at a significantly greater risk (p = 0.003) of sustaining a vertebral fracture than patients whose BMD increased. The fracture risk was similar (about 10%) in risedronate-treated patients whose increases in BMD were < 5% (the median change from baseline) and in those whose increases were ? 5% (p = 0.453). The changes in lumbar spine BMD explained only 18% (95% confidence interval [CI], 10%, 26%; p < 0.001) of risedronate's vertebral fracture efficacy. Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk.
This record has no associated files available for download.
More information
Published date: 2004
Keywords:
bone mineral density, vertebral fractures, risedronate, surrogate measure, osteoporosis, antiresorptive therapy
Identifiers
Local EPrints ID: 26116
URI: http://eprints.soton.ac.uk/id/eprint/26116
ISSN: 1094-6950
PURE UUID: d7768828-28af-4992-8564-c22583798e6c
Catalogue record
Date deposited: 12 Apr 2006
Last modified: 18 Mar 2024 02:44
Export record
Contributors
Author:
Nelson B. Watts
Author:
Robert Lindsay
Author:
Richard Eastell
Author:
Michael D. Manhart
Author:
Ian P. Barton
Author:
Tjeerd-Pieter van Staa
Author:
Jonathan D. Adachi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics